Abbott Laboratories Is Down 22%. What History Says Now.

Abbott Laboratories Is Down 22%. What History Says.

Abbott Laboratories (ABT) is now down 22% from its all-time high as of August 6, 2026, having just exited the red zone after 512 days. The Drawdown Severity Score™ has improved to 4.7, placing the stock in the yellow zone. In 12 comparable prior recoveries of this depth, the stock took an average of 642 days to resolve the drawdown.

Abbott's Transition Out of the Red Zone

As of August 6, 2026, the market data shows a shift in the drawdown profile for Abbott Laboratories. The stock has transitioned from the high-risk red zone into the yellow zone, which represents a significant severity level. This movement is reflected in the current Drawdown Severity Score™ of 4.7.

The transition indicates that while the asset remains in a deep pullback, the immediate downward momentum has slowed enough to lift it out of the most severe category. Investors tracking the stock will note that this change comes after a prolonged period of downward pressure. The current price of $107.96 represents a partial recovery from the lowest points of the current cycle.

By crossing this threshold, the asset has modified its risk profile according to our historical models. The move to a severity score of 4.7 means the stock is no longer in the maximum risk tier, though it remains far from its historical peak. We track these zone changes to help identify when long-term trends may be beginning to shift.

Measuring the Depth and Duration of the Current Drawdown

To understand the scale of the current pullback, we must look at the exact distance from the peak. Abbott Laboratories reached its all-time high of $138.33 before entering this current drawdown cycle. At the current price of $107.96, the stock has experienced a drawdown of exactly -22.0%.

This drawdown has now persisted for 512 days as of August 6, 2026. A duration of over 500 days places this event among the more persistent pullbacks in the company's trading history. It represents a sustained departure from the stock's typical behavior during standard market cycles.

Our historical database contains 297 total drawdown events for Abbott Laboratories. Across all of these historical events, the average maximum drawdown was only -4.4%. This highlights just how unusual the current -22.0% decline is when compared to the asset's long-term historical norm.

Furthermore, the average duration of all historical drawdowns for this stock is 46 days. The current duration of 512 days is more than ten times longer than the average historical recovery period. This massive divergence emphasizes the prolonged nature of the current cycle and the scale of the recovery required to reach new highs.

Historical Context: How Prior 20% Drawdowns Resolved

Throughout its trading history, Abbott Laboratories has dropped by 20% or more from its peak on only 12 occasions. This small number of occurrences indicates that a 20% decline is a relatively rare event for this particular asset. When these deep pullbacks do occur, they typically require a substantial amount of time to resolve.

The average duration of these 12 comparable drops is 642 days. This average duration includes the time spent falling from the peak to the trough, as well as the time required to recover back to the previous all-time high. The current drawdown of 512 days is approaching this historical average, suggesting that the stock is deep into its typical recovery timeline.

Comparing the current metrics to these historical averages provides clear structural context for the current recovery phase. The table below contrasts the current drawdown metrics against the historical averages for all drawdowns and the subset of drawdowns exceeding 20%.

This historical data shows that once Abbott Laboratories enters a deep drawdown of this magnitude, the path back to all-time highs is rarely rapid. The 642-day average recovery duration for 20%+ drops indicates that long-term patience has historically been required. The current 512-day duration shows that the current cycle is maturing relative to those historical precedents.

The Impact of Structural Shifts on Historical Comparisons

While historical comparisons provide valuable context, we must apply an honest caveat when analyzing these 12 comparable events. A sample size of 12 occurrences over several decades of trading history is statistically small. This limited dataset means that past performance metrics may not perfectly predict future outcomes.

Additionally, the structural profile of Abbott Laboratories has changed significantly over time. The most notable corporate action occurred on January 1, 2013, when the company completed the spin-off of its research-based pharmaceuticals business into a separate publicly traded entity, AbbVie (ABBV). This spin-off fundamentally altered Abbott's business model, revenue mix, and overall volatility profile.

Prior to 2013, the stock's price movements and drawdown characteristics reflected a combined medical device, diagnostics, nutritional, and pharmaceutical giant. Post-spin-off, Abbott became a more focused medical technology and diagnostics company. Consequently, drawdown events that occurred before 2013 may not be directly comparable to the stock's modern behavior.

The volatility dynamics of the post-2013 entity are distinct from those of the legacy corporation. This structural shift means that the historical 642-day average recovery period contains data from a different corporate structure. Investors should consider this limitation when comparing the current 512-day drawdown to older historical cycles.

Technical Levels: The Thresholds That Matter Now

To evaluate the progress of the current recovery, we can look at specific price thresholds based on the peak price of $138.33. These exact price points represent key milestones that would alter the current drawdown profile and severity score.

The current price of $107.96 places the stock exactly at a -22.0% drawdown. If the stock experiences renewed downward pressure, a drop to $103.75 would represent a drawdown of exactly -25.0%. Slipping past this level would likely trigger a return to the high-severity red zone, signaling that the recovery has stalled.

Conversely, to move further upward and transition to the next, less severe zone, the stock must reclaim higher price levels. A move to $110.66 would bring the drawdown to exactly -20.0%. Reclaiming this level would represent a key technical milestone, potentially improving the Drawdown Severity Score™ further.

The table below outlines the exact price levels associated with key drawdown percentages based on the all-time high of $138.33.

Monitoring these exact price targets allows investors to track Abbott's progress without relying on subjective assessments. The price of $103.75 remains the critical downside level to watch, as falling below it would erase the recent stabilization that led to the yellow zone transition.

Scope of This Price-Based Analysis

This drawdown analysis is built entirely on historical price data, peak-to-trough measurements, and duration statistics. It does not incorporate fundamental metrics, earnings results, macroeconomic indicators, or qualitative news events. By focusing exclusively on the mathematical properties of the stock's price cycles, we provide an un-skewed view of market structure.

The patterns observed in the 297 historical drawdown events reflect how market participants have historically responded during periods of distribution and accumulation. While these historical patterns offer a framework for understanding risk, they do not constitute financial advice or guarantees of future performance.

The transition from the red zone to the yellow zone indicates a statistical shift in momentum, but the asset remains in a significant drawdown. Whether the stock continues its recovery toward the -20.0% threshold at $110.66 or falls back toward the red-zone trigger of $103.75 depends on ongoing market auction dynamics.